Wallington Asset Management’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Wallington Asset Management’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-390	Closed	-$24K	–	115
2014 Q2	$24K	Hold	390	–	–	0.01%	79
2014 Q1	$22K	Buy	+390	New	+$22.1K	0.01%	85

Other funds holding PJP

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

NCM

Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

FIG

FundX Investment Group San Francisco, California $411M AUM 22.05% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Wallington Asset Management's PJP Position: Q3 2014 in Review

Wallington Asset Management sold out of Invesco Pharmaceuticals ETF (PJP) in Q3 2014, closing a stake of 390 shares — an estimated $24K sold.

Wallington Asset Management first reported a position in PJP in Q1 2014 and held it in 2 quarters. The position peaked at $24K in Q2 2014. 90 funds tracked by Wall St. Rank hold PJP as of Q3 2014.

Wallington Asset Management reported no remaining Invesco Pharmaceuticals ETF position as of Q3 2014 after selling out during the quarter.
Wallington Asset Management sold 390 Invesco Pharmaceuticals ETF shares in Q3 2014, an estimated $24K.
Wallington Asset Management first reported a position in Invesco Pharmaceuticals ETF in Q1 2014 and held it in 2 quarters.
Wallington Asset Management's Invesco Pharmaceuticals ETF position peaked at $24K in Q2 2014.
90 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q3 2014.

Based on Wallington Asset Management's 13F filing for Q3 2014, filed 28 Oct 2014.